Malaria Panel (4 targets)
Malaria Panel (4 targets)

[Product Name]

4 Malaria Pathogen Nucleic Acid Detection Kit (Fluorescent PCR-Chip Method)

Malaria  Panel (4 targets) CHE-MLP4-101

[Packing Specifications]

12 tests / box

[Applicable Models]

Multi-Disc (Model: CQ-0404) Fully Automated Nucleic Acid Analyzer

[Download Brochure]

Malaria  Panel (4 targets)Chenghui-Multi-Disc-4-Malaria-Pathogen-Nucleic-Acid-Detection-Kit-Brochure.pdf



No Data

Testing Process

No Data

Intended Use


4 Malaria Pathogen Nucleic Acid Detection Kit (Fluorescent PCR-Chip Method) is a Fluorescent PCR-Chip assay intended for the qualitative detection of malaria parasites in human venous whole blood (EDTA anticoagulant) samples, including:

  1. Plasmodium spp., 

  2. Plasmodium falciparum, 

  3. Plasmodium vivax,

  4. Plasmodium knowlesi.

Challenges


Malaria remains one of the world’s most life-threatening parasitic infectious diseases, with high morbidity and mortality across tropical and subtropical regions. Rising cross-border travel and trade have also steadily increased the risk of imported cases in non-endemic countries. For tertiary hospital infectious disease departments, border quarantine authorities and frontline public health agencies, conventional malaria diagnostic approaches have four core unmet needs:


Limited accuracy and subtyping capacity of conventional testing

Traditional gold-standard microscopy relies heavily on experienced technicians, with low sensitivity for low-parasitemia infections that often lead to missed diagnoses. Rapid diagnostic tests (RDTs) only offer limited differentiation between Plasmodium falciparum and non-falciparum strains, and cannot accurately identify species such as Plasmodium knowlesi — which is easily misidentified via microscopy — or distinguish relapsing Plasmodium vivax. This lack of precise subtyping leads to inappropriate antimalarial therapy, unaddressed relapse risks, and delayed recognition of life-threatening severe falciparum malaria.


Delayed diagnosis misses the narrow treatment window for severe malaria

Severe P. falciparum malaria can progress to organ failure and death within hours, requiring prompt targeted antimalarial intervention. Conventional nucleic acid testing relies on centralized molecular laboratories, with lengthy sample transport and batch processing workflows that delay results by hours to days. This lag directly worsens patient prognosis and slows on-site quarantine clearance at ports of entry.


High operational barriers limit access in endemic and frontline settings

Standard PCR-based malaria testing requires standardized molecular laboratories and certified technical personnel. These resources are largely unavailable in remote malaria-endemic regions, grassroots medical facilities, border checkpoints and field outbreak sites, leaving vast gaps in access to reliable, high-sensitivity malaria testing.


Mounting pressure for imported malaria prevention and surveillance

Growing international mobility has driven a steady rise in imported malaria cases in non-endemic regions. Conventional on-site tests lack the sensitivity to detect low-parasitemia imported infections, creating risks of local secondary transmission. Additionally, the increasing prevalence of zoonotic P. knowlesi is not fully covered by many routine testing panels, creating further missed diagnosis risks.


Core Benefits


The 4 Malaria Pathogen Nucleic Acid Detection Kit, paired with the Multi-Disc fully automated nucleic acid analysis platform, directly addresses the above clinical and public health pain points:


Malaria  Panel (4 targets)One-stop 4-plex profiling for accurate Plasmodium identification and subtyping

A single run covers 4 targets: pan-Plasmodium (genus-level screening), P. falciparum, P. vivax and P. knowlesi. It delivers both initial infection confirmation and precise species differentiation, clearly identifying high-lethality falciparum malaria, relapsing vivax malaria and easily misdiagnosed knowlesi malaria. This enables clinicians to select targeted antimalarial regimens accurately, reduce inappropriate medication, and lower risks of severe disease and recurrence.


Results in around 80 minutes to seize the severe malaria treatment window

Total testing time is around 80 minutes, with only 1 minute of hands-on sample loading — far faster than centralized laboratory PCR workflows. Rapid species-level results enable clinicians to initiate targeted antimalarial therapy promptly, reducing mortality from severe malaria. It also supports on-site rapid quarantine at ports of entry to speed up entry screening and block imported case transmission risks.


Low-barrier POCT deployment to expand testing accessibility

Powered by the fully automated closed Multi-Disc platform, the assay requires no standardized molecular laboratory or specialized technical staff. It can be deployed directly in infectious disease departments, grassroots clinics, border quarantine stations and endemic field sites, with on-demand testing for samples as they arrive. This significantly shortens diagnostic turnaround time and extends access to high-quality molecular malaria testing to underserved settings.


High-sensitivity nucleic acid detection to support precision public health control

Built on real-time fluorescent PCR technology, the assay delivers far higher sensitivity and specificity than microscopy and RDTs, and can detect low-parasitemia early-stage and asymptomatic infections. It reduces missed diagnosis rates, supports early detection and isolation of imported cases, and facilitates efficient epidemiological surveillance and malaria elimination programs.


Core Product Advantages


Guideline-aligned 4-plex panel for dual clinical and public health use

The panel covers pan-Plasmodium and three clinically critical malaria species (P. falciparum, P. vivax, P. knowlesi), fully aligned with WHO malaria testing guidelines. It is suitable for severe malaria diagnosis, travel medicine screening, entry-exit port quarantine and endemic outbreak surveillance, meeting the needs of both tertiary hospitals and public health agencies.


Fully automated closed sample-to-result workflow

Leveraging proprietary centrifugal microfluidic technology, the kit integrates two gold-standard workflows — silica membrane-based nucleic acid extraction and multiplex real-time qPCR — within a single enclosed disposable cartridge. Only 1 minute of manual pipetting is required, with no professional molecular operation expertise needed, delivering true "load-and-go" detection.

Malaria  Panel (4 targets)


Flexible throughput adapted to diverse testing scenarios

Compatible with the Multi-Disc (Model: CQ-0404) Fully Automated Nucleic Acid Analyzer, the platform supports parallel testing of 4 samples per run with full results available in around 80 minutes. It supports flexible 1–4 sample loading without batch accumulation, adapting seamlessly to sporadic emergency testing, on-demand port quarantine and mass field screening.


Lyophilized reagents for room-temperature storage and transport

With our self-developed PCR reagent lyophilization process, pre-embedded lyophilized reagent beads in the microfluidic chip enable room-temperature storage and transportation, eliminating cold chain reliance. This greatly reduces storage and logistics costs for tropical endemic regions, remote grassroots sites and field testing scenarios.


Zero cross-contamination closed cartridge system

Each sample is processed in an individual sealed disposable cartridge, with amplification products never exposed to the external environment. This design fundamentally eliminates aerosol cross-contamination, reduces on-site quality control burdens, and ensures stable, reliable results even in non-laboratory field settings.


CE-compliant with validated whole blood sample compatibility

The assay is fully validated for human venous whole blood samples with EDTA anticoagulation. All 4 targets are CE-marked, meeting regulatory requirements for clinical diagnosis, public health surveillance and border quarantine across global markets.